Table 2.
Effects of different covariates on progression-free survival
| Covariates | Relative risk | Confidence interval | P |
|---|---|---|---|
| Univariate analysis | |||
| SULtotal | 1.0510 | 1.0200–1.0829 | 0.0012 |
| SUVmax | 1.1069 | 1.0413–1.1768 | 0.0012 |
| CMR | 0.1580 | 0.0447–0.5583 | 0.0044 |
| Number of lesions | 1.0722 | 1.0214–1.1254 | 0.0050 |
| Bone metastases | 3.3701 | 1.2746–8.9108 | 0.0148 |
| Presence of metastases | 3.1435 | 1.1888–8.3124 | 0.0216 |
| Liver metastases | 3.2010 | 1.1791–8.6898 | 0.0231 |
| ED vs LD | 2.8198 | 1.0866–7.3181 | 0.0340 |
| Age | 1.0150 | 0.9724–1.0594 | 0.4986 |
| PMR | 1.2264 | 0.4660–3.2274 | 0.6809 |
| SMD | 0.9350 | 0.2746–3.1831 | 0.9148 |
| Gender | 0.9987 | 0.3815–2.6146 | 0.9979 |
| Multivariate analysis | |||
| CMR | 0.2069 | 0.0540–0.7923 | 0.0221 |
| Presence of metastases | 3.0456 | 1.0661–8.7002 | 0.0386 |
| SULtotal | 1.0305 | 0.9975–1.0646 | 0.0719 |